ABY 035

Drug Profile

ABY 035

Alternative Names: ABY-035; AFB-035

Latest Information Update: 27 Feb 2016

Price : $50

At a glance

  • Originator Affibody
  • Class Anti-inflammatories
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis
  • Preclinical Inflammation

Most Recent Events

  • 01 Feb 2016 Phase-I clinical trials in Psoriasis in United Kingdom (SC and IV) (NCT02690142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top